Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
Open Access
- 11 October 2010
- journal article
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1), 1-7
- https://doi.org/10.1186/1475-2875-9-275
Abstract
Background: Artemether-lumefantrine is one of the most widely used anti-malarial drug combinations in the world with excellent tolerability and cure rates in adult and paediatric patients with uncomplicated falciparum malaria. The aim of this study was to evaluate the pharmacokinetics of artemether and its active metabolite, dihydroartemisinin, in healthy Pakistani volunteers. Methods: Twelve healthy male Pakistani subjects, aged 20 to 50, were recruited into the study. A fixed oral combination of artemether-lumefantrine (80-480 mg) was given as a single oral dose. Frequent blood samples were collected and artemether and dihydroartemisinin were quantified in human plasma using solid-phase extraction and liquid chromatography coupled with tandem mass spectrometry. Drug concentration-time data were evaluated with non-compartmental analysis. Results: Observed maximum concentrations (mean ± SD) of artemether and dihydroartemisinin were 184 ± 100 ng/mL and 126 ± 46 ng/mL, respectively. These concentrations were reached at 1.56 ± 0.68 hr and 1.69 ± 0.59 hr, respectively, after drug intake. The terminal elimination half-life of artemether and dihydroartemisinin were 2.00 ± 0.71 hr and 1.80 ± 0.31 hr, respectively. Apparent volume of distribution and oral clearance for artemether were estimated to 666 ± 220 L and 257 ± 140 L/hr. The same parameters were estimated to 702 ± 220 L and 269 ± 57 L/hr for dihydroartemisinin. Conclusions: The overall pharmacokinetic properties of artemether and dihydroartemisinin in healthy Pakistani subjects are comparable to healthy subjects and patients from other populations.Keywords
This publication has 25 references indexed in Scilit:
- A Liquid Chromatographic–Tandem Mass Spectrometric Method for Determination of Artemether and its Metabolite Dihydroartemisinin in Human PlasmaBioanalysis, 2009
- Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions*1Clinical Pharmacology & Therapeutics, 2004
- Pharmacokinetics and electrocardiographic pharmacodynamics of artemether‐lumefantrine (Riamet®) with concomitant administration of ketoconazole in healthy subjectsBritish Journal of Clinical Pharmacology, 2002
- A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand.The American Journal of Tropical Medicine and Hygiene, 2001
- Pharmacokinetics of Artemisinin-Type CompoundsClinical Pharmacokinetics, 2000
- Ethnic Differences in Drug Disposition and ResponseTherapeutic Drug Monitoring, 1998
- The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects.European Journal of Drug Metabolism and Pharmacokinetics, 1998
- Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteersBritish Journal of Clinical Pharmacology, 1997
- Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivativesTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria.British Journal of Clinical Pharmacology, 1994